BACK ISSUES of PULLAN'S PIECES
May 2024- Pullan's Pieces #203
Linda: IPOs of 2024
Linda: Market cap per employee and other stats by territory
Kristine: Option Deals in BiotechTrevor: Market Sentiment: Marking Time?
April 2024 - Pullan's Pieces #202
Linda: Radiopharmaceuticals
Linda: Impact of orphan designation
Kristine: Synthetic royalty structures
Trevor: Market sentiment: which way do we go?
March 2024- Pullan's Pieces #201
Linda: Ono snapshot
Linda: Competition and market share
Kristine: ADCs
Trevor: Market sentiment. PE around 18?
February 2024- Pullan's Pieces #200
Linda: India and Innovation
Linda: Peptides
Kristine: Vectors in Gene Medicines
Trevor: Market Sentiment: Risk-free rates of return?
January 2024- Pullan's Pieces #199
Linda: How different are different Therapeutic areas?
Linda: BioNtech snapshot
Kristine: 2024 – A Turnaround Year
Trevor: Market Sentiment: Good news on earnings?
November 2023- Pullan's Pieces #198
Linda: 2023 Discovery Deals
Linda: GSK- a snapshot
Kristine: 2024 Outlook
Trevor: Market Sentiment: US investment in China
October 2023 - Pullan's Pieces #197
Linda: 3rd Quarter Partnering Analysis
Linda: Top 10 sellers of 2023 US approved drugs
Kristine: More likely to succeed modalities
Trevor: Market Sentiment: XBI still down
September 2023- Pullan's Pieces #196
Linda: Eli Lilly Snapshot
Linda: Pediatric Oncology Trials and Deals
Kristine: Option-to-License Deals in Cell & Gene Therapy
Trevor: Market Sentiment: Down Rounds
August 2023 - Pullan's Pieces #195
Linda: Boehringer Ingelheim snapshot
Linda: China's economy - impact on biotech deals
Kristine: Impact of US Inflation Reduction Act
Trevor: Market Sentiment - Not Easy
July 2023 - Pullan's Pieces #194
Linda: Protac - an update
Linda: Talking to the right person?
Kristine: Cell and Gene Therapy Landscape
Trevor: Market Sentiment - Frozen
June 2023 - Pullan's Pieces #193
Linda: Sanofi- a snapshot
Linda: Amendments to Licenses
Kristine: Licensing deal trends
Trevor: Market sentiment - Up or down?
May 2023- Pullan's Pieces #192
Linda: Deal terminations in 2023
Linda: Why deals fail to get signed? What to do?
Kristine: GPCRs
Trevor: Bio Focus and Raises in Oncology